Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity

Overview

Journal Cancer Res

Specialty Oncology

Date 2006 Sep 5

PMID 16951202

Citations 162

Authors

Shuzhong Zhang

Katherine S Lovejoy

James E Shima

Leah L Lagpacan

Yan Shu

Anna Lapuk

Ying Chen

Takafumi Komori

Joe W Gray

Xin Chen

Stephen J Lippard

Kathleen M Giacomini

Affiliations

Soon will be listed here.

Abstract

Although the platinum-based anticancer drugs cisplatin, carboplatin, and oxaliplatin have similar DNA-binding properties, only oxaliplatin is active against colorectal tumors. The mechanisms for this tumor specificity of platinum-based compounds are poorly understood but could be related to differences in uptake. This study shows that the human organic cation transporters (OCT) 1 and 2 (SLC22A1 and SLC22A2) markedly increase oxaliplatin, but not cisplatin or carboplatin, accumulation and cytotoxicity in transfected cells, indicating that oxaliplatin is an excellent substrate of these transporters. The cytotoxicity of oxaliplatin was greater than that of cisplatin in six colon cancer cell lines [mean +/- SE of IC(50) in the six cell lines, 3.9 +/- 1.4 micromol/L (oxaliplatin) versus 11 +/- 2.0 micromol/L (cisplatin)] but was reduced by an OCT inhibitor, cimetidine, to a level similar to, or even lower than that of, cisplatin (29 +/- 11 micromol/L for oxaliplatin versus 19 +/- 4.3 micromol/L for cisplatin). Structure-activity studies indicated that organic functionalities on nonleaving groups coordinated to platinum are critical for selective uptake by OCTs. These results indicate that OCT1 and OCT2 are major determinants of the anticancer activity of oxaliplatin and may contribute to its antitumor specificity. They also strongly suggest that expression of OCTs in tumors should be investigated as markers for selecting specific platinum-based therapies in individual patients. The development of new anticancer drugs, specifically targeted to OCTs, represents a novel strategy for targeted drug therapy. The results of the present structure-activity studies indicate specific tactics for realizing this goal.

Citing Articles

Multitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain.

Babu T, Muthuramalingam R, Chng W, Yau J, Acharya S, Engelmayer N J Med Chem. 2025; 68(2):1608-1618.

PMID: 39779280 PMC: 11770746. DOI: 10.1021/acs.jmedchem.4c02263.

Impact of genetic variants in the solute carrier () genes encoding drug uptake transporters on the response to anticancer chemotherapy.

Marin J, Serrano M, Herraez E, Lozano E, Ortiz-Rivero S, Perez-Silva L Cancer Drug Resist. 2024; 7:27.

PMID: 39143954 PMC: 11322974. DOI: 10.20517/cdr.2024.42.

OCT1 (SLC22A1) transporter kinetics and regulation in primary human hepatocyte 3D spheroids.

Mickols E, Meyer A, Handin N, Stuwe M, Eriksson J, Rudfeldt J Sci Rep. 2024; 14(1):17334.

PMID: 39068198 PMC: 11283471. DOI: 10.1038/s41598-024-67192-6.

Evaluation of 14 PFAS for permeability and organic anion transporter interactions: Implications for renal clearance in humans.

Ryu S, Yamaguchi E, Modaresi S, Agudelo J, Costales C, West M Chemosphere. 2024; 361:142390.

PMID: 38801906 PMC: 11774580. DOI: 10.1016/j.chemosphere.2024.142390.

Mechanisms of Sorafenib Resistance in HCC Culture Relate to the Impaired Membrane Expression of Organic Cation Transporter 1 (OCT1).

Chava S, Ekmen N, Ferraris P, Aydin Y, Moroz K, Wu T J Hepatocell Carcinoma. 2024; 11:839-855.

PMID: 38741679 PMC: 11090194. DOI: 10.2147/JHC.S452152.

References

Gorboulev V, Ulzheimer J, Akhoundova A, Karbach U, Quester S, Baumann C . Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997; 16(7):871-81. DOI: 10.1089/dna.1997.16.871. View

Lebwohl D, Canetta R . Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer. 1999; 34(10):1522-34. DOI: 10.1016/s0959-8049(98)00224-x. View

Raymond E, Chaney S, Taamma A, Cvitkovic E . Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998; 9(10):1053-71. DOI: 10.1023/a:1008213732429. View

Desoize B, Madoulet C . Particular aspects of platinum compounds used at present in cancer treatment. Crit Rev Oncol Hematol. 2002; 42(3):317-25. DOI: 10.1016/s1040-8428(01)00219-0. View

Goldberg R . Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005; 10 Suppl 3:40-8. DOI: 10.1634/theoncologist.10-90003-40. View

Samimi G, Safaei R, Katano K, Holzer A, Rochdi M, Tomioka M . Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res. 2004; 10(14):4661-9. DOI: 10.1158/1078-0432.CCR-04-0137. View

Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K . Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol. 2005; 70(12):1823-31. DOI: 10.1016/j.bcp.2005.09.020. View

Szakacs G, Annereau J, Lababidi S, Shankavaram U, Arciello A, Bussey K . Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell. 2004; 6(2):129-37. DOI: 10.1016/j.ccr.2004.06.026. View

Pinto A, Lippard S . Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta. 1985; 780(3):167-80. DOI: 10.1016/0304-419x(85)90001-0. View

10.

Leabman M, Huang C, Kawamoto M, Johns S, Stryke D, Ferrin T . Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002; 12(5):395-405. DOI: 10.1097/00008571-200207000-00007. View

11.

Chaney S, Campbell S, Bassett E, Wu Y . Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol. 2004; 53(1):3-11. DOI: 10.1016/j.critrevonc.2004.08.008. View

12.

Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota H . Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005; 167(6):1477-84. PMC: 1613191. DOI: 10.1016/S0002-9440(10)61234-5. View

13.

Giandomenico C, Abrams M, Murrer B, Vollano J, Rheinheimer M, Wyer S . Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. Inorg Chem. 2009; 34(5):1015-21. DOI: 10.1021/ic00109a004. View

14.

Alley M, Scudiero D, Monks A, Hursey M, Czerwinski M, Fine D . Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 1988; 48(3):589-601. View

15.

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

16.

Fink D, Zheng H, Nebel S, Norris P, Aebi S, Lin T . In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997; 57(10):1841-5. View

17.

Holzer A, Samimi G, Katano K, Naerdemann W, Lin X, Safaei R . The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2004; 66(4):817-23. DOI: 10.1124/mol.104.001198. View

18.

Woynarowski J, Chapman W, Napier C, Herzig M, Juniewicz P . Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol. 1998; 54(5):770-7. DOI: 10.1124/mol.54.5.770. View

19.

Muller J, Lips K, Metzner L, Neubert R, Koepsell H, Brandsch M . Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005; 70(12):1851-60. DOI: 10.1016/j.bcp.2005.09.011. View

20.

Kelly H, Goldberg R . Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005; 23(20):4553-60. DOI: 10.1200/JCO.2005.17.749. View